News | Intra-Aortic Balloon Pumps (IABP) | June 06, 2018

FDA Class 1 Recall of Maquet Datascope IABPs Due to Fluid Seepage

Maquet Datascope Corp. is recalling the CardioSave Hybrid Intra-aortic Balloon Pump (IABP).

The touchscreen Maquet Datascope CardioSave Hybrid Intra-aortic Balloon Pump (IABP) system console.

June 6, 2018 — Maquet Datascope Corp. said it is recalling the CardioSave Hybrid Intra-aortic Balloon Pump (IABP) due to fluid ingress that may affect device operation, interrupt or delay therapy. 

The U.S. Food and Drug Administration (FDA) issued a safety alert today that stated a design issue in the IABP can allow fluid (such as saline) to seep into the device. The fluid can cause corrosion of internal components such as the electronic circuit boards. The FDA said this can lead to device malfunction like sudden stops, which can cause a delay or interruption in therapy. The FDA said device failure may result in immediate and serious adverse health consequences, including death. 

The recall includes CardioSave Hybrid IABP part numbers: 0998-00-0800-XX, 0998-UC-0800-XX and cart 0997-00-1179 (excluding 0998-00-0800-83, 0998-UC-0800-83 & 0998-00-0800-75). The FDA said all lots are affected by this recall. 

The manufacturing dates include Dec 12, 2011 through April 25, 2018. The distribution dates were between March 6, 2012 to April 26, 2018. 

The CardioSave IABP is a cardiac assist device used with patients undergoing cardiac and non-cardiac surgery, and to treat patients with acute coronary syndrome or complications from heart failure, the FDA stated. 

Recommendations for Users: 

   • Never place fluids on top of the unit

   • Ensure that the saline container and tubing do not hang directly over the IABP

   • In case of accidental spillage, to wipe clean immediately and have the unit serviced to ensure no hazard exists.

   • In case of an interruption in therapy, the letter instructed users to:

   • Transfer the patient to an alternative IABP   

   • If an alternative IABP is unavailable, manually inflate the IAB with air or helium and immediately aspirate repeat every five minutes until either an alternate IABP is available or alternatively (i.e., if an alternative IABP is not available in a reasonable amount of time) the intra-aortic balloon catheter should be removed from the patient.

 

The FDA said affected customers will be contacted by Maquet Datascope Corp. to schedule on-site service of the IABP by a Maquet Datascope Corp. sales or service representative. The company anticipates having the protective top cover available by late June 2018.

U.S. customers wanting more information about this recall can contact Maquet Datascope Corp.’s Technical Support Department at 1-888-627-8383 (press option 3), Monday through Friday, between 8 a.m. and 6 p.m. Eastern Standard Time.

Healthcare professionals and patients are encouraged to report adverse events or side effects related to the use of these products to the FDA's MedWatch Safety Information and Adverse Event Reporting Program at www.fda.gov/MedWatch/report.

Link to FDA Safety Alerts in 2018
 

Related Content

Shockwave Launches Coronary Intravascular Lithotripsy in Europe
News | Cath Lab | May 30, 2018
Shockwave Medical recently announced the European commercial availability of Intravascular Lithotripsy (IVL) for...
FFR software on the GE Centricity CVIS. A trial from the 2018 EuroPCR meeting showed FFR improves long-term outcomes.
News | Cath Lab | May 29, 2018
May 29, 2018 — Ongoing controversy exists regarding the role of percutaneous coronary intervention (PCI) for stable c
SCAI Updates Consensus on Length of Stay for Percutaneous Coronary Intervention
News | Cath Lab | May 15, 2018
Revised guidelines incorporating new data on discharge criteria for patients undergoing elective percutaneous coronary...
No Benefit Found Using Sodium Bicarbonate, Acetylcysteine to Prevent Kidney Injury, the result of the PRESERVE Trial to prevent acute kidney injury (AKI), presented at SCAI 2018.  #SCAI, #SCAI2018,
Feature | Cath Lab | May 15, 2018
May 15, 2018 – The large-scale, international randomized PRESERVE clinical trial found high-risk patients for renal c
Angiogram of a STEMI patient.
News | Cath Lab | May 15, 2018
May 15, 2018 — A contemporary, real-world analysis shows lower mortality rates when culprit-only intervention is used
Recent Acquisitions Eroding Prices in Billion Dollar European Interventional Cardiology cath lab Market.
Feature | Cath Lab | May 07, 2018 | Simon Trinh and Jeffrey Wong
The European interventional cardiology market is currently valued at nearly $1.4 billion.
Videos | Cath Lab | May 07, 2018
Imran Ahmad, M.D., medical director of interventional cardiology, explains some of the new technologies his labs have
360 Photos | Cath Lab | April 20, 2018
A 360 degree view of the newest cath lab at Northwestern Medicine Central DuPage Hospital in Winfield, Ill., located
SCAI Announces Global Lecture Series for 2018 Scientific Sessions
News | Cath Lab | April 18, 2018
Many of the world’s leading interventional cardiologists and cardiovascular professionals will convene in San Diego,...
Serial coronary angiograms of the representative case treated with shockwave intravascular lithotripsy.

Figure 1. Serial coronary angiograms of the representative case treated with shockwave intravascular lithotripsy.

Feature | Cath Lab | April 16, 2018 | Azeem Latib, M.D.
Over the last decade, there have been considerable developments in procedural techniques and technology facilitating
Overlay Init